BI 44847

Drug Profile

BI 44847

Alternative Names: BI44847

Latest Information Update: 01 Oct 2014

Price : $50

At a glance

  • Originator Ajinomoto
  • Developer Boehringer Ingelheim
  • Class
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Japan (PO) (NCT02211924)
  • 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Germany (PO, Powder) (NCT02209844)
  • 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Germany (PO, Suspension, Liquid, Tablet) (NCT02211937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top